APOC3 and clostridium difficile infection: Taken together, these findings point towards APOC3 as a potential drug target to reduce inflammation in myeloid-derived cells in vivo and link the glucosyltransferase-independent effect to a broader understanding of the CDI setting and the subsequent inflammatory diseases.